MCM
ALNY icon

Murphy Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Murphy Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,600
Closed -$230K – 319
2013
Q3 		$230K Buy
+3,600
New +$179K 0.04% 278

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Murphy Capital Management's ALNY Position: Q4 2013 in Review

Murphy Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2013, closing a stake of 3,600 shares — an estimated $230K sold.

Murphy Capital Management first reported a position in ALNY in Q3 2013 and held it in 1 quarter. The position peaked at $230K in Q3 2013. 169 funds tracked by Wall St. Rank hold ALNY as of Q4 2013.

  • Murphy Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Murphy Capital Management sold 3,600 Alnylam Pharmaceuticals shares in Q4 2013, an estimated $230K.
  • Murphy Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Murphy Capital Management's Alnylam Pharmaceuticals position peaked at $230K in Q3 2013.
  • 169 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2013.

Based on Murphy Capital Management's 13F filing for Q4 2013, filed 10 Jan 2014.